Peer-reviewedLicence not statedLancet Oncology
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Related
- Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
- The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials
- Effect of dapagliflozin on renal response in patients with biopsy-confirmed lupus nephritis receiving stable maintenance immunosuppression and renin–angiotensin system inhibition: protocol for the multicentre randomised DAPA-LN trial
- Impact of educational actions on the quality of life of patients with epilepsy: A randomised controlled trial
- Investigating the Efficacy of the Proactive Automatised Lifestyle intervention among general hospital patients (ePAL): study protocol of a randomised controlled trial.
BibTeX
@article{poveda2026olaparib,
title = {{Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial}},
author = {Andrés Poveda and Anne Floquet and Jonathan Ledermann and Rebecca Asher and Richard Penson and Amit Oza and Jacob Korach and Tomasz Huzarski and Sandro Pignata and Michael Friedlander and Alessandra Baldoni and Tjoung-Won Park-Simon and Kenji Tamura and Gabe Sonke and Alla Lisyanskaya and Jae-Hoon Kim and Elias Abdo Filho and Tsveta Milenkova and Elizabeth Lowe and Phil Rowe and Ignace Vergote and Eric Pujade-Lauraine and Jacob Korach and Tomasz Huzarski and Tomasz Byrski and Patricia Pautier and Michael Friedlander and Philipp Harter and Nicoletta Colombo and Sandro Pignata and Giovanni Scambia and Maria Nicoletto and Fiona Nussey and Andrew Clamp and Richard Penson and Amit Oza and Andrés Poveda Velasco and Manuel Rodrigues and Jean-Pierre Lotz and Frédéric Selle and Isabelle Ray-Coquard and Diane Provencher and Aleix Prat Aparicio and Laura Vidal Boixader and Clare Scott and Kenji Tamura and Mayu Yunokawa and Alla Lisyanskaya and Jacques Medioni and Nicolas Pécuchet and Coraline Dubot and Thibault de la Motte Rouge and Marie-Christine Kaminsky and Béatrice Weber and Alain Lortholary and Christine Parkinson and Jonathan Ledermann and Sarah Williams and Susana Banerjee and Jonathan Cosin},
journal = {Lancet Oncology},
year = {2026},
month = sep,
doi = {10.1016/s1470-2045(21)00073-5},
url = {https://hal.science/hal-05742842v1},
}
RIS
TY - JOUR
TI - Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
AU - Andrés Poveda
AU - Anne Floquet
AU - Jonathan Ledermann
AU - Rebecca Asher
AU - Richard Penson
AU - Amit Oza
AU - Jacob Korach
AU - Tomasz Huzarski
AU - Sandro Pignata
AU - Michael Friedlander
AU - Alessandra Baldoni
AU - Tjoung-Won Park-Simon
AU - Kenji Tamura
AU - Gabe Sonke
AU - Alla Lisyanskaya
AU - Jae-Hoon Kim
AU - Elias Abdo Filho
AU - Tsveta Milenkova
AU - Elizabeth Lowe
AU - Phil Rowe
AU - Ignace Vergote
AU - Eric Pujade-Lauraine
AU - Jacob Korach
AU - Tomasz Huzarski
AU - Tomasz Byrski
AU - Patricia Pautier
AU - Michael Friedlander
AU - Philipp Harter
AU - Nicoletta Colombo
AU - Sandro Pignata
AU - Giovanni Scambia
AU - Maria Nicoletto
AU - Fiona Nussey
AU - Andrew Clamp
AU - Richard Penson
AU - Amit Oza
AU - Andrés Poveda Velasco
AU - Manuel Rodrigues
AU - Jean-Pierre Lotz
AU - Frédéric Selle
AU - Isabelle Ray-Coquard
AU - Diane Provencher
AU - Aleix Prat Aparicio
AU - Laura Vidal Boixader
AU - Clare Scott
AU - Kenji Tamura
AU - Mayu Yunokawa
AU - Alla Lisyanskaya
AU - Jacques Medioni
AU - Nicolas Pécuchet
AU - Coraline Dubot
AU - Thibault de la Motte Rouge
AU - Marie-Christine Kaminsky
AU - Béatrice Weber
AU - Alain Lortholary
AU - Christine Parkinson
AU - Jonathan Ledermann
AU - Sarah Williams
AU - Susana Banerjee
AU - Jonathan Cosin
PY - 2026
DA - 2026/09/08
JO - Lancet Oncology
DO - 10.1016/s1470-2045(21)00073-5
UR - https://hal.science/hal-05742842v1
SN - 1470-2045
SN - 1474-5488
ER -